Financial Performance - In the first three quarters of 2024, the company's revenue was CNY 464.95 million, a decrease of 2.33% year-on-year [2] - In Q3 2024, the revenue was CNY 159.29 million, down 13.28% year-on-year [2] - The net profit for the first three quarters was CNY 99.32 million, a decline of 51.60% year-on-year [2] - In Q3 2024, the net profit was CNY 28.37 million, down 59.20% year-on-year [2] - The decline in net profit is attributed to a decrease in unconventional business income and fluctuations in cash management [2] Business Development and Strategy - The company is focusing on integrating SCB in product technology, personnel, and market aspects, with expected long-term synergies [3] - The company aims to establish a "one-stop" platform for biological reagents and technical services to meet diverse customer needs [3] - The overseas market has been expanding, with stable growth in revenue contributions primarily from the U.S., while other regions are experiencing rapid growth [3] Research and Development - R&D expenses are primarily allocated to core business extensions, including upgrades in key protein reagents and development of new products [4] - The company is enhancing its antibody technology platform and has launched several new antibody products [4] - The development and sales of cytokine products are ongoing, with new products being optimized and revenue growth observed, although they currently represent a small portion of total revenue [4]
义翘神州(301047) - 2024年10月29日投资者关系活动记录表